Compared with these results, although we lack of the data of sRAGE in our current study, it can be proposed that the RAGE rs2070600 polymorphic variant A allele might be linked with decreased level of sRAGE in prostate cancer, thereby decreasing the risk to develop grade group upgrade in prostate cancer patients, especially in those grade group upgrade patients whose PSA ≤ 10 (Tables 2 and 3). Here, AGER is linked to prostate carcinoma.